Table 1.
Tumor pathology and patients’ characteristics.
| Characteristics | Number of patients (%) |
|---|---|
| Age, years | |
| ≤40 | 33 (9.2) |
| >40 | 326 (90.8) |
| Menstruation status | |
| Premenopause | 135 (37.6) |
| Postmenopause Body mass index, kg/m2 | 224 (62.4) |
| <30 | 321 (89.4) |
| ≥30 | 38 (10.6) |
| Tumor location | |
| Outer upper quadrant | 173 (48.2) |
| Inner upper quadrant | 95 (26.5) |
| Outer lower quadrant | 50 (13.9) |
| Inner lower quadrant | 32 (8.9) |
| Central region | 9 (2.5) |
| Side of the tumor | |
| Left | 183 (50.9) |
| Right | 176 (49.1) |
| Pathological type | |
| IDC | 333 (92.7) |
| ILC | 14 (3.9) |
| Mucous carcinoma | 6 (1.7) |
| Other | 6 (1.7) |
| Tumor size (mm) | |
| <20 | 195 (54.3) |
| ≥20 and ≤ 50 | 162 (45.1) |
| >50 | 2 (0.6) |
| Estrogen receptor | |
| Positive | 270 (75.2) |
| Negative | 89 (24.8) |
| Progesterone receptor | |
| Positive | 232 (64.6) |
| Negative | 127 (35.4) |
| Ki-67 expression levels | |
| <14% | 57 (15.9) |
| ≥14% | 302 (84.1) |
| HER2 state | |
| Positive | 143 (39.8) |
| Negative | 216 (60.2) |
| Histological grade | |
| I | 46 (12.8) |
| II | 249 (69.4) |
| III | 64 (17.8) |
| Lymphovascular invasion | |
| Present | 28 (7.8) |
| Absent | 331 (92.2) |
| Multifocality | |
| Multifocal | 19 (5.3) |
| Unifocal | 340 (94.7) |
| Molecular subtypes | |
| Luminal A | 49 (13.6) |
| Luminal B | 220 (61.3) |
| HER2 positive | 51 (14.2) |
| Triple negative | 39 (10.9) |
| Number of dissected SLNs | |
| 1 | 80 (22.2) |
| 2 | 88 (24.5) |
| 3 | 62 (17.4) |
| ≥4 | 129 (35.9) |
| Number of metastatic lymph nodes | |
| 0 | 205 (57.2) |
| ≤3 | 119 (33.1) |
| ≥4 and ≤9 | 26 (7.2) |
| ≥10 | 9 (2.5) |
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor 2; SLNs, sentinel lymph nodes.